The Elan Effect - - BioPharm International

ADVERTISEMENT

The Elan Effect

BioPharm International


Elan is building on its breakthrough research and extensive experience in Alzheimer's disease and is also studying other neurodegenerative disorders, such as Parkinson's disease. Two of Elan's compounds from the Alzheimer's disease immunotherapy program, in collaboration with Wyeth, are currently progressing through clinical trials. Dosing of patients with ACC-001 in a Phase I clinical trial began in the third quarter of 2005. Phase II trials of the humanized monoclonal antibody AAB-001, designed and engineered to remove the neurotoxic beta-amyloid peptide that accumulates in the brains of patients with Alzheimer's disease, began in the first half of 2005.

Conclusion

As it emerges from a challenging period, Elan Corporation remains committed to filling significant unmet medical needs by bringing scientific innovations in science to market. Its proprietary NanoCrystal technology offers substantial patient benefit, and its research in the areas of inflammatory and neuropathic pain, autoimmune diseases, and neurology hold promise to relieve patient suffering.

Paradoxically, the company's challenges also have spawned broader growth in the Irish biopharmaceuticals industry. Former Elan executives have launched new companies such as Azur Pharm Limited, AGI Therapeutics Limited, Merrion Pharmaceuticals, Inc., PharmaPlaz, PK Pharma Innovations Limited, InfoSight Corporation, BioClin Research Laboratories, and a venture fund and a life sciences law practice. Focused on a range of services ranging from new therapeutic areas to drug delivery and analytical support services, these companies are contributing to the strengthening of the biopharmaceuticals sector in Ireland.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here